SecBot SecBot
PRESS-RELEASE ·Filed Mar 13, 2026

VACH

Voyager Acquisition Corp.
BEARISH
Impact 8/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▼ Bearish

The extreme redemption rate signals strong investor rejection of VERAXA as a target. Traders should watch for low float dynamics and potential volatility upon listing as VRXA, with high risk of weak post-merger performance typical of 'redemption-heavy' SPACs.

DirectionBearish
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
VACH ▲ +20.11% at T+60d
SHORT call ✗ call lost -20.11% · α vs SPY -8.50% · entry $10.74 → $12.90
Entry = T+0 close
Mar 13, 2026
via day close
T+1d
-1.77%
call +1.77% · α +2.79%
$10.55
settled 8mo ago
T+5d
-2.23%
call +2.23% · α +0.12%
$10.50
settled 7mo ago
T+20d
+14.06%
call -14.06% · α -10.47%
$12.25
settled 7mo ago
T+60d
+20.11%
call -20.11% · α -8.50%
$12.90
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Voyager Acquisition Corp. (VACH) has approved its business combination with VERAXA Biotech AG, with 99.67% of shareholders electing to redeem their shares, leaving only $885,556 in the trust account and 82,685 Class A shares post-redemption. The combined company is expected to trade under the new ticker 'VRXA' pending Nasdaq listing approval.

Key Financial Metrics

Deal Value
$885.6K

Key Facts

  • 99.67% of VACH Class A shares were redeemed — 25,217,315 shares out of 25,300,000 outstanding
  • Only $885,556 remains in trust post-redemption, down from ~$253 million (assuming $10/share trust value)
  • Post-transaction, only 82,685 shares will remain, indicating extreme shareholder dilution and loss of investor confidence
  • Combined entity to trade as VRXA on Nasdaq, pending listing approval
  • Deal reflects a near-total collapse of SPAC investor interest, typical of a failed or unattractive target

Financial Impact

Trust value reduced from ~$253 million to $885,556 due to redemptions; equity base shrinks from ~25.3M to 82,685 shares

cashequitydilutionmarket_cap

Risk Factors

  • Extremely low post-transaction cash may impair VERAXA’s ability to fund operations or clinical development
  • Minimal public float could lead to illiquidity and price manipulation risks
  • High risk of post-merger underperformance given lack of market confidence

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3255326
2 reports for VACH
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VACH — sortable, filterable
TypeNow
Mar 13, 2026
32w ago
Press Release
BEARISH ★ 8/10
$10.74 $12.90▼ −20.11%▼ −8.50%—
Mar 11, 2026
32w ago
Press Release
BEARISH ★ 8/10
$12.19 $9.76▲ +19.93%▲ +31.46%—
Showing 2 of 2

US Market Status

Market Closed — Opens Wed (11h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 13, 2026